Back to search
Carcinoma in Situ
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Carcinoma in Situ trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Carcinoma in Situ trials you may qualify forThe pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T…
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patient…
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an earl…
This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast su…
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Inc…
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC.…
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with…
This study will evaluate the local control, complication rates, cosmetic results, and quality of life between patients treated with a single fraction vs. five f…